Real-world use and impact of direct oral anticoagulants among atrial fibrillation patients with cardioembolic stroke - Takeaways - MDSpire

Real-world use and impact of direct oral anticoagulants among atrial fibrillation patients with cardioembolic stroke

  • By

  • Vladislavs Sokaļskis

  • Kaspars Kupics

  • Kristaps Jurjāns

  • Nikolajs Ņesterovičs

  • Ieva Ozoliņa

  • Guntis Karelis

  • Evija Miglāne

  • Andrejs Ērglis

  • June 18, 2026

  • 0 min

Share

  • 1

    Atrial fibrillation (AF) significantly increases the risk of cardioembolic stroke (CES), accounting for about 30% of ischemic events.

  • 2

    Non-adherence to direct oral anticoagulants (DOACs) is prevalent among AF patients, with 55.8% not taking them regularly in Latvia.

  • 3

    Patients on DOACs prior to CES experienced significantly milder strokes compared to non-users, with lower NIHSS scores.

  • 4

    Stroke patients on DOAC therapy had larger left atrial volume indices than those not on therapy, indicating potential thrombotic risk.

  • 5

    This study highlights the need for improved adherence to DOACs to reduce stroke severity and improve outcomes in AF patients.

Original Source(s)

Real-world use and impact of direct oral anticoagulants among atrial fibrillation patients with cardioembolic stroke

  • by Vladislavs Sokaļskis, Kaspars Kupics, Kristaps Jurjāns, Nikolajs Ņesterovičs, Ieva Ozoliņa, Guntis Karelis, Evija Miglāne, Andrejs Ērglis

  • June 18, 2026

Related Content

Clinical features of type A aortic dissection initially presenting with neurological symptoms: a single-center case series

Prediction Models for Post-Stroke Delirium: A Systematic Review with an Exploratory Meta-Analysis of Predictors

Brain cell-released Cyclophilin A induces neuroinflammation and exacerbates blood–brain barrier injury in acute ischemic stroke